{
    "Clinical Trial ID": "NCT01923168",
    "Intervention": [
        "INTERVENTION 1: ",
        "  Alpelisib + Letrozole",
        "  Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.",
        "INTERVENTION 2: ",
        "  Placebo + Letrozole",
        "  Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily."
    ],
    "Eligibility": [
        "Inclusion Criteria:",
        "  Patient is an adult, female  18 years old at the time of informed consent",
        "  Patient has a histologically and/or cytologically confirmed diagnosis of breast cancer",
        "  Patient is postmenopausal.",
        "  Patient has T1c-T3, any N, M0, operable breast cancer",
        "  Patients must have measurable disease",
        "  Patient has diagnostic biopsy available for the analysis of PIK3CA mutation and Ki67 level.",
        "  Patient has estrogen-receptor and/or progesterone positive breast cancer as per local laboratory testing",
        "  Patient has HER2 negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0 or 1+ as per local laboratory testing",
        "Exclusion Criteria:",
        "  Patient has locally recurrent or metastatic disease",
        "  Patient has received any systemic therapy (e.g. chemotherapy, targeted therapy, immunotherapy) or radiotherapy for current breast cancer disease before randomization.",
        "  Patient with type 1 diabetes mellitus or not adequately controlled type 2 diabetes mellitus",
        "  History of acute pancreatitis within 1 year of study entry",
        "  Uncontrolled hypertension"
    ],
    "Results": [
        "Outcome Measurement: ",
        "  Pathological Complete Response (pCR) Per Investigator Assessment for Alpelisib vs. Placebo for PIK3CA Mutant Cohort",
        "  Pathologic complete response (pCR) defined as absence of any residual invasive cancer on hematoxylin and eosin evaluation of the resected breast specimen and all sampled ipsilateral lymph nodes following completion of 24 weeks of treatment by local assessment (ypT0/Tis ypN0). Patients who experienced progression of disease while undergoing neoadjuvant therapy, or who did not receive surgery for any reason, or received antineoplastic treatment other than study drug(s) before surgery were considered as non-responders for the calculation of pCR rate.",
        "  Time frame: After 24 weeks of treatment",
        "Results 1: ",
        "  Arm/Group Title: Alpelisib + Letrozole",
        "  Arm/Group Description: Participants took alpelisib 300 mg once daily plus letrozole 2.5 mg once daily.",
        "  Overall Number of Participants Analyzed: 60",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of Participants  1.7        (0.2 to 6.3)",
        "Results 2: ",
        "  Arm/Group Title: Placebo + Letrozole",
        "  Arm/Group Description: Participants took matching Placebo (of alpelisib 300 mg once daily/buparlisib 100 mg once daily or 5 days on/2 days off) plus Letrozole 2.5 mg once daily.",
        "  Overall Number of Participants Analyzed: 67",
        "  Measure Type: Number",
        "  Unit of Measure: Percentage of Participants  3.0        (0.8 to 7.7)"
    ],
    "Adverse Events": [
        "Adverse Events 1:",
        "  Total: 21/130 (16.15%)",
        "  Atrial fibrillation 0/130 (0.00%)",
        "  Cardiac disorder 0/130 (0.00%)",
        "  Cardiac failure 1/130 (0.77%)",
        "  Stress cardiomyopathy 1/130 (0.77%)",
        "  Iritis 0/130 (0.00%)",
        "  Colitis 1/130 (0.77%)",
        "  Diarrhoea 1/130 (0.77%)",
        "  Nausea 1/130 (0.77%)",
        "  Stomatitis 1/130 (0.77%)",
        "  Vomiting 1/130 (0.77%)",
        "  Disease progression 1/130 (0.77%)",
        "Adverse Events 2:",
        "  Total: 22/81 (27.16%)",
        "  Atrial fibrillation 2/81 (2.47%)",
        "  Cardiac disorder 1/81 (1.23%)",
        "  Cardiac failure 0/81 (0.00%)",
        "  Stress cardiomyopathy 0/81 (0.00%)",
        "  Iritis 1/81 (1.23%)",
        "  Colitis 2/81 (2.47%)",
        "  Diarrhoea 1/81 (1.23%)",
        "  Nausea 0/81 (0.00%)",
        "  Stomatitis 0/81 (0.00%)",
        "  Vomiting 0/81 (0.00%)",
        "  Disease progression 0/81 (0.00%)",
        "  General physical health deterioration 1/81 (1.23%)"
    ]
}